MTVA (MetaVia) Short Percentage of Float

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MTVA MetaVia Inc MTVA
30 GF Score
Price $1.42
! 1 Warning Sign
View Full Analysis

What is MetaVia Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.


MTVA vs CNSP, TRAW, APRE: Short Percentage of Float Comparison

For the Biotechnology subindustry, MetaVia's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MetaVia Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MetaVia's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where MetaVia's Short Percentage of Float falls into.


MTVA
30GF Score
MetaVia Inc MTVA
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MetaVia Business Description

Address 545 Concord Avenue, Suite 210, Cambridge, MA, USA, 02138
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.
30GF Score

Get the complete analysis for MTVA

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.42
Price